Ian Estepan | Senior Vice President, Chief of Staff and Corporate Affairs |
Douglas Ingram | President and Chief Executive Officer |
Sandy Mahatme | Executive Vice President, Chief Financial Officer and Chief Business Officer |
Bo Cumbo | Executive Vice President and Chief Commercial Officer |
Louise Rodino-Klapac | Senior Vice President, Gene Therapy |
Gilmore O'Neill | Executive Vice President, R&D and Chief Medical Officer |
Alethia Young | Cantor Fitzgerald |
Tazeen Ahmad | Bank of America Merrill Lynch |
Brian Abrahams | RBC Capital Markets |
Christopher Marai | Nomura |
Vincent Chen | Bernstein |
Brian Skorney | Robert W. Baird |
Danielle Brill | Piper Jaffray |
Timothy Lugo | William Blair |
Ross Weinreb | Goldman Sachs |
Joseph Schwartz | SVB Leerink |
Timothy Chiang | BTIG |
Liisa Bayko | JMP Securities |
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics Second Quarter 2019 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's program is being recorded.
And now, I would like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs.